
04/06/2025
GP synposium 2025
Venue: Ascott Gurney
Date: 31st May 2025
Presentation topic: Bridging the Gap in AD Management: From Topicals to Targeted Systemic Therapies
I’m excited to share with fellow general practitioners two of the latest advancements in the management of atopic dermatitis (AD): Crisaborole ointment and Abrocitinib, the newest JAK inhibitor recently registered in Malaysia.
Crisaborole is a non-steroidal topical treatment designed to manage active AD lesions effectively, offering a steroid-sparing option for patients with mild to moderate disease.
For patients with moderate to severe AD that is inadequately controlled with topicals, Abrocitinib offers a powerful oral targeted therapy. Clinical studies have shown that Abrocitinib can provide itch relief within just one day, with a 50% reduction in lesions seen within one week.
I’m pleased to share that both of these cutting-edge treatments are now available at my clinic at Island Hospital, Penang.